Biotechnology
Harbour BioMed Announces IND Approval for Next-Gen Anti-TSLP Fully Human Monoclonal Antibody
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Feb. 21, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that China National Medical Products Administration (NMPA) had approved its investigational new drug (IND) application for HBM9378 (or SKB378 as referred to ...
2022-02-21 20:29
2135
Biosion, Inc. Appoints Joel Edwards, MBA, as Chief Business Officer
NEWARK, Del. and NANJING, China, Feb. 21, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical stage biotechnology company, today announced the appointment ofJoel Edwards as chief business officer. In this position, he is responsible for strategic leadership over all aspects of the c...
2022-02-21 13:00
1651
Innovent Announces First Patient Dosing of Universal "Modular" CAR-T Cell product IBI345
SAN FRANCISCO and SUZHOU, China, Feb. 21, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2022-02-21 08:00
3103
OliPass Announces Commencement of Dosing in Phase 2a Trial for Pain Killer OLP-1002
SEOUL, South Korea, Feb. 18, 2022 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced that the dosing of pain killer OLP-1002 commenced for a Phase 2a trial in osteoarthritis patients with pain. The Phase 2a study was appr...
2022-02-18 23:00
3102
Keymed Bio Joins Hang Seng Family of Indexes
HONG KONG, Feb. 18, 2022 /PRNewswire/ -- According to the quarterly review results of Hang Seng Family of Indexes, Keymed Biosciences Inc. (2162. HK) was included a constituent stock of: * Hang Seng Composite Index; * Hang Seng Small Cap (Investable) Index; * Hang Seng Stock Connect Hong K...
2022-02-18 22:10
6445
PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology
- Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically - Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma MELBOURNE, Australia, Feb. 18, 2022 /PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on ...
2022-02-18 08:19
1698
Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma
SUZHOU, China and PALO ALTO, Calif., Feb. 17, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today...
2022-02-17 21:30
2517
Flat Medical joins the Stay Connected(R), the International Organization for Safer Neuraxial Anesthesia
TAIPEI, Feb. 17, 2022 /PRNewswire/ -- Flat Medical Co., Ltd., a MedTech company specializing in safety solutions for anesthesia and critical care procedures, has announced that it has just joined the Stay Connected®, a joint communication initiative on behalf of the industry to advocate and educa...
2022-02-17 21:00
1571
Small Molecule Targeting CD47-SIRPα Pathway: Insilico Medicine Achieves its First Major Milestone in Fosun Pharma Collaboration with the Nomination of Preclinical Candidate for QPCTL
SHANGHAI and NEW YORK, Feb. 17, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery and development company, today announced that it has used its proprietary AI platform to nominate a preclinical candidate compound (PCC) for innova...
2022-02-17 16:30
2412
BioWorld by Clarivate Provides In-depth Analyses of Long COVID Studies, Potentially the Next Public Health Crisis
40-plus therapeutics in development even as researchers are trying to reach consensus on the syndrome LONDON, Feb. 17, 2022 /PRNewswire/ -- BioWorld published by Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, has ann...
2022-02-17 16:00
2910
Kato Wins FDA Approval for Human Studies of Drug for Retinal Disorders
Resolv ER™ may remedy leading causes of blindness in adults LAGUNA HILLS, Calif., Feb. 17, 2022 /PRNewswire/ -- Kato Pharmaceuticals, a privately-held clinical stage biopharmaceutical company, today announced that the FDA has approved the company's investigational new drug (IND) application to c...
2022-02-17 12:14
2227
CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for Pralsetinib for the Treatment of RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) and RET-Altered Thyroid Cancers in Taiwan, China
SUZHOU, China, Feb. 17, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the Taiwan Food and Drug A...
2022-02-17 09:19
4141
Innovent Announces Two Registration Studies of IBI306 (anti-PCSK-9 antibody) Met Primary Endpoint
SAN FRANCISCO and SUZHOU, China, Feb. 17, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major dise...
2022-02-17 08:00
3947
PharmaBlock Appoints Dr. Zhengtian Gu as Senior Vice President of Quality and Regulatory Affairs
NANJING, China, Feb. 16, 2022 /PRNewswire/ -- PharmaBlock (300725.SZSE), an innovative chemistry products and services provider to support drug discovery, development, and commercialization, announces the appointment of Dr. Zhengtian (Titan) Gu as Senior Vice President of Quality and Regulatory A...
2022-02-16 20:00
1560
Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)
HONG KONG, Feb. 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or " Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that they have received the "safe to proceed" letter from the U.S. Food and Drug Adminis...
2022-02-16 17:04
3069
NIBIOHN, Shionogi Discover Host Immune-dependent Novel Anti-coronavirus Antibody
OSAKA, Japan, Feb. 16, 2022 /PRNewswire/ -- The National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN;Ibaraki-shi, Osaka; Director-general:Yoshihiro Yoneda), in partnership with Shionogi & Co., Ltd. (Chuo-ku,Osaka; President and CEO: Isao Teshirogi), has successfully identif...
2022-02-16 14:00
2346
Delos Capital Announces $300 Million First Close of its Third Life Sciences Fund
HONG KONG, Feb. 15, 2022 /PRNewswire/ -- Delos Capital, a Hong Kong -headquartered life sciences venture capital fund with a global presence and investment mandate, announces the successful$300 million first close of its Fund III. The first close of Fund III was completed in only 6 months of fun...
2022-02-15 23:59
2579
Goodwin Biotechnology Announces the Appointment of Darrin T. Schellin as Chief Executive Officer
PLANTATION, Fla., Feb. 15, 2022 /PRNewswire/ -- Goodwin Biotechnology, Inc. is pleased to announce a key appointment designed to accelerate its growth significantly and scale the company into the future.Darrin Schellin joins the company as Chief Executive Officer and will also be inducted as a me...
2022-02-15 22:35
2142
Travecta Therapeutics Appoints Leading Experts to Expand its Scientific Advisory Leadership Team
PRINCETON, N.J. and SINGAPORE, Feb. 15, 2022 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd., a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, today announced significant expansion of the Scientific Advisory B...
2022-02-15 21:00
1558
Travecta Therapeutics Appoints Leading Experts to Expand its Scientific Advisory Leadership Team
PRINCETON, N.J. and SINGAPORE, Feb. 15, 2022 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd., a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, today announced significant expansion of the Scientific Advisory B...
2022-02-15 21:00
1970
Week's Top Stories
Most Reposted
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 303 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 296 media titles]
2024-11-28 17:24MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 280 media titles]
2024-11-25 10:00
Announcement of "Cyber Sousa Award" Winners of the 16th Xiamen International Animation Festival
[Picked up by 272 media titles]
2024-11-26 16:48
Most Read
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
12324
SUNLU Formnext 2024 Event Highlights: From Functional Filaments to FilaDryer E2
2024-11-23 21:00
8375
Innovative technology and applications recognised with Hong Kong ICT Awards 2024
2024-11-23 02:02
8090
MMA SMARTIES Thailand 2024 - Celebrates Unparalleled Marketing Innovation and Excellence in Thailand
2024-11-23 11:00
7519
WeBank Powers Fusion Bank's Rapid Launch of a Next-Generation Core Banking System
2024-11-22 15:21
5841